Efalizumab for the treatment of moderate to severe plaque psoriasis.
about
Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.Efalizumab-induced autoimmune pancytopenia.Absence of β2 integrins impairs regulatory T cells and exacerbates CD4+ T cell-dependent autoimmune carditisMolecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.Efalizumab
P2860
Efalizumab for the treatment of moderate to severe plaque psoriasis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Efalizumab for the treatment of moderate to severe plaque psoriasis.
@ast
Efalizumab for the treatment of moderate to severe plaque psoriasis.
@en
type
label
Efalizumab for the treatment of moderate to severe plaque psoriasis.
@ast
Efalizumab for the treatment of moderate to severe plaque psoriasis.
@en
prefLabel
Efalizumab for the treatment of moderate to severe plaque psoriasis.
@ast
Efalizumab for the treatment of moderate to severe plaque psoriasis.
@en
P2860
P356
P1476
Efalizumab for the treatment of moderate to severe plaque psoriasis.
@en
P2093
Joseph K Jordan
P2860
P304
P356
10.1345/APH.1G074
P407
P577
2005-07-05T00:00:00Z